{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:52:38Z","timestamp":1789602758095,"version":"build-2803163510"},"reference-count":39,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100011102","name":"European Union Seventh Framework Programme","doi-asserted-by":"crossref","award":["609020"],"award-info":[{"award-number":["609020"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Oslo Diabetes Research Centre"},{"name":"Lund University Diabetes Center","award":["2009-1039"],"award-info":[{"award-number":["2009-1039"]}]},{"name":"Lund University Diabetes Center","award":["349-2006-23"],"award-info":[{"award-number":["349-2006-23"]}]},{"name":"Lund University Diabetes Center","award":["IRC15-006"],"award-info":[{"award-number":["IRC15-006"]}]},{"DOI":"10.13039\/501100003173","name":"Crafoordska Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006189","name":"Direkt\u00f6r Albert P\u00e5hlssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Methylglyoxal (MGO), a reactive aldehyde forming advanced glycation end products (AGEs), is increased in diabetes and recognized by the immune system, resulting in anti-AGE\u2013specific autoantibodies. The association of these immune responses with macro- and microvascular complications in type 1 diabetes remains unclarified. We investigated associations between MGO-modified apolipoprotein B100 (apoB100) and apoB100 peptide 5 (MGO-p5) autoantibodies and coronary atherosclerosis and retinopathy in type 1 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>IgM and IgG against MGO-apoB100 and MGO-p5 were measured by ELISA in plasma from 103 subjects with type 1 diabetes and 63 control subjects (Dialong study) and in a replication cohort of 27 subjects with type 1 diabetes (Oslo study). Coronary atherosclerosis was assessed by computed tomography coronary angiography or intravascular ultrasound. Retinopathy was classified by retinal photos.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>MGO-apoB100 IgM and MGO-p5 IgM levels were higher in subjects with diabetes with no coronary artery stenosis compared with subjects with significant stenosis (median [interquartile range]: 96.2 arbitrary units [AU] [71\u2013126.8] vs. 54 AU [36.1\u201385.4], P\u2008= 0.003 for MGO-apoB100; and 77.4 AU [58\u2013106] vs. 36.9 AU [28.9\u201357.4], P\u2008= 0.005 for MGO-p5). MGO-apoB100 IgM and MGO-p5 IgM were associated with less severe coronary stenosis after adjusting for confounders (odds ratio 0.2 [95% CI 0.05\u20130.6], P\u2008= 0.01; and 0.22 [0.06\u20130.75], P\u2008= 0.02). The inverse association of MGO-p5 IgM and coronary stenosis was confirmed in the replication cohort. Subjects with proliferative retinopathy had significantly lower MGO-apoB100 IgM and MGO-p5 IgM than those with background retinopathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Autoantibodies against AGE-modified apoB100 are inversely associated with coronary atherosclerosis and proliferative retinopathy, suggesting vascular protective effects of these autoantibodies in type 1 diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-2089","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T16:26:25Z","timestamp":1618503985000},"page":"1402-1409","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":8,"title":["Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes"],"prefix":"10.2337","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-9965","authenticated-orcid":false,"given":"Kari Anne","family":"Sveen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-4271","authenticated-orcid":false,"given":"Kristine","family":"Bech Holte","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Svanteson","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian F.","family":"Hanssen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-7479","authenticated-orcid":false,"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Sk\u00e5ne University Hospital, Lund University, Malm\u00f8, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Sk\u00e5ne University Hospital, Lund University, Malm\u00f8, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Julsrud Berg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"2022051611113289400_B1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"2022051611113289400_B2","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"key":"2022051611113289400_B3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.2337\/dc18-0476","article-title":"The association of severe diabetic retinopathy with cardiovascular outcomes in long-standing type 1 diabetes: a longitudinal follow-up","volume":"41","author":"Pongrac Barlovic","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051611113289400_B4","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.2337\/dc18-1236","article-title":"Atherosclerosis and microvascular complications: results from the Canadian Study of Longevity in Type 1 Diabetes","volume":"41","author":"Lovshin","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051611113289400_B5","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0140-6736(08)60767-9","article-title":"Type 1 diabetes, hyperglycaemia, and the heart","volume":"371","author":"Retnakaran","year":"2008","journal-title":"Lancet"},{"key":"2022051611113289400_B6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1463-1326.2006.00595.x","article-title":"Advanced glycation endproducts: what is their relevance to diabetic complications?","volume":"9","author":"Ahmed","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"2022051611113289400_B7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1755-3768.2008.01300.x","article-title":"Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced glycation endproduct hydroimidazolone","volume":"87","author":"Fosmark","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"2022051611113289400_B8","doi-asserted-by":"crossref","first-page":"31038","DOI":"10.1074\/jbc.M704703200","article-title":"High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A","volume":"282","author":"Yao","year":"2007","journal-title":"J Biol Chem"},{"key":"2022051611113289400_B9","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2337\/db11-0085","article-title":"Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes","volume":"60","author":"Rabbani","year":"2011","journal-title":"Diabetes"},{"key":"2022051611113289400_B10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00125-004-1648-4","article-title":"Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells","volume":"48","author":"Brown","year":"2005","journal-title":"Diabetologia"},{"key":"2022051611113289400_B11","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1742-4658.2007.05699.x","article-title":"Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein \u03b2-100 protein in primary human monocyte-derived macrophages","volume":"274","author":"Brown","year":"2007","journal-title":"FEBS J"},{"key":"2022051611113289400_B12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1194\/jlr.M200370-JLR200","article-title":"Autoimmune response to advanced glycosylation end-products of human LDL","volume":"44","author":"Virella","year":"2003","journal-title":"J Lipid Res"},{"key":"2022051611113289400_B13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2011.07.017","article-title":"Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression","volume":"58","author":"Tsimikas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2022051611113289400_B14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2796.2011.02411.x","article-title":"High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes","volume":"271","author":"Engelbertsen","year":"2012","journal-title":"J Intern Med"},{"key":"2022051611113289400_B15","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.4049\/jimmunol.1402869","article-title":"Low levels of IgM antibodies against an advanced glycation endproduct-modified apolipoprotein B100 peptide predict cardiovascular events in nondiabetic subjects","volume":"195","author":"Engelbertsen","year":"2015","journal-title":"J Immunology"},{"key":"2022051611113289400_B16","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1167\/iovs.07-1440","article-title":"Intraretinal leakage and oxidation of LDL in diabetic retinopathy","volume":"49","author":"Wu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2022051611113289400_B17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s00125-009-1377-9","article-title":"Associations between autoantibodies against apolipoprotein \u03b2-100 peptides and vascular complications in patients with type 2 diabetes","volume":"52","author":"Fredrikson","year":"2009","journal-title":"Diabetologia"},{"key":"2022051611113289400_B18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/01.ATV.0000067935.02679.B0","article-title":"Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease","volume":"23","author":"Fredrikson","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022051611113289400_B19","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2337\/db19-0358","article-title":"Immune complexes and the risk of CVD in type 1 diabetes","volume":"68","author":"Lopes-Virella","year":"2019","journal-title":"Diabetes"},{"key":"2022051611113289400_B20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.atherosclerosis.2006.02.007","article-title":"Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes","volume":"190","author":"Lopes-Virella","year":"2007","journal-title":"Atherosclerosis"},{"key":"2022051611113289400_B21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCULATIONAHA.118.036068","article-title":"Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus","volume":"139","author":"Sousa","year":"2019","journal-title":"Circulation"},{"key":"2022051611113289400_B22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jdiacomp.2017.06.007","article-title":"Hand, shoulder and back stiffness in long-term type 1 diabetes; cross-sectional association with skin collagen advanced glycation end-products. The Dialong study","volume":"31","author":"Holte","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2022051611113289400_B23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3132\/dvdr.2007.009","article-title":"Intracoronary ultrasound examinations reveal significantly more advanced coronary atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls","volume":"4","author":"Larsen","year":"2007","journal-title":"Diab Vasc Dis Res"},{"key":"2022051611113289400_B24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jdiacomp.2019.01.006","article-title":"Undiagnosed coronary artery disease in long-term type 1 diabetes. The Dialong study","volume":"33","author":"Holte","year":"2019","journal-title":"J Diabetes Complications"},{"key":"2022051611113289400_B25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12933-019-0861-x","article-title":"Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography","volume":"18","author":"Svanteson","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022051611113289400_B26","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.2337\/dc13-0788","article-title":"Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study","volume":"36","author":"Sveen","year":"2013","journal-title":"Diabetes Care"},{"key":"2022051611113289400_B27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022051611113289400_B28","doi-asserted-by":"crossref","first-page":"20437","DOI":"10.1074\/jbc.M117.806307","article-title":"Advanced glycation end products impair NLRP3 inflammasome-mediated innate immune responses in macrophages","volume":"292","author":"Son","year":"2017","journal-title":"J Biol Chem"},{"key":"2022051611113289400_B29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","article-title":"Role of advanced glycation end products in cellular signaling","volume":"2","author":"Ott","year":"2014","journal-title":"Redox Biol"},{"key":"2022051611113289400_B30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1172\/JCI4533","article-title":"Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins","volume":"103","author":"H\u00f6rkk\u00f6","year":"1999","journal-title":"J Clin Invest"},{"key":"2022051611113289400_B31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/dc17-2250","article-title":"Differential association of microvascular attributions with cardiovascular disease in patients with long duration of type 1 diabetes","volume":"41","author":"Gordin","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051611113289400_B32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2337\/dc12-1311","article-title":"Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial","volume":"36","author":"Gerstein","year":"2013","journal-title":"Diabetes Care"},{"key":"2022051611113289400_B33","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.2337\/dc13-0669","article-title":"Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes","volume":"36","author":"H\u00e4gg","year":"2013","journal-title":"Diabetes Care"},{"key":"2022051611113289400_B34","first-page":"49","article-title":"Sex differences in inflammation during atherosclerosis","volume":"8","author":"Fairweather","year":"2015","journal-title":"Clin Med Insights Cardiol"},{"key":"2022051611113289400_B35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0021-9150(92)90260-N","article-title":"Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects","volume":"93","author":"Tames","year":"1992","journal-title":"Atherosclerosis"},{"key":"2022051611113289400_B36","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1161\/01.CIR.0000092891.55157.A7","article-title":"Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis","volume":"108","author":"Karvonen","year":"2003","journal-title":"Circulation"},{"key":"2022051611113289400_B37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1194\/jlr.M600361-JLR200","article-title":"Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events","volume":"48","author":"Tsimikas","year":"2007","journal-title":"J Lipid Res"},{"key":"2022051611113289400_B38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.109.868158","article-title":"Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"120","author":"Lewis","year":"2009","journal-title":"Circulation"},{"key":"2022051611113289400_B39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/08916934.2017.1280669","article-title":"Opposing roles of B lymphocyte subsets in atherosclerosis","volume":"50","author":"Kyaw","year":"2017","journal-title":"Autoimmunity"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-2089","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/6\/1402\/632546\/dc202089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/6\/1402\/632546\/dc202089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:13:20Z","timestamp":1652699600000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/6\/1402\/138705\/Autoantibodies-Against-Methylglyoxal-Modified"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,15]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-2089","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}